We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The liver disease profile provides an invaluable resource relating to one of the main causes of premature mortality nationally.
Bulletin containing main points from the update of indicators in the liver disease profile.
Data update of indicators in the liver disease profiles interactive tool.
Evidence and information to help healthcare professionals raise awareness of risk factors for liver disease.
The semaglutide injection has been approved to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).